Latest news with #Plc
Yahoo
17-06-2025
- Business
- Yahoo
Aspo Plc - Managers' Transactions
Aspo Plc Managers' transactions June 17, 2025, at 5.30 p.m. Aspo Plc - Managers' Transactions - Mikko Pasanen ____________________________________________ Person subject to the notification requirement Name: Mikko Pasanen Position: Other senior manager Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 112438/4/4____________________________________________ Transaction date: 2025-06-16 Venue: OFF-EXCHANGE LIIKETOIMET (XOFF) Instrument type: DEBT INSTRUMENT ISIN: FI4000523170 Nature of transaction: DISPOSAL Transaction details (1): Volume: 100000 Unit price: 100 PCT Aggregated transactions (1): Volume: 100000 Volume weighted average price: 100 PCTAspo Plc Erkka Repo CFO For further information, please contact: Erkka Repo, CFO, tel. +358 40 582 7971, Distribution: Nasdaq Helsinki creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 17 different countries, and it employs approximately 800 professionals. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "We remain laser focused on becoming a key player in the ADC space and advancing our novel ADC platform built around immuno-oncology payloads and our lead asset AKTX-101, an ADC targeting Trop2 with our immuno-oncology payload, PH1. We continue to develop and execute a clear path forward for our ADC pipeline and support these efforts with ongoing activities and building the team that we believe positions us for success in the near and long term,' commented Abizer Gaslightwala, President and Chief Executive Officer of Akari. 'In particular, we were pleased to recently welcome Mark Kubik, a seasoned leader in the Antibody Drug Conjugate space, as Head of Business Development, Oncology and believe his expertise will be invaluable as we continue to advance our novel ADC platform technology.' Leveraging its innovative payload platform, the Company is advancing a pipeline of potentially first-in-class, best-in-class ADC candidates across a wide range of cancer tumor targets. These initial candidates have shown significant tumor-killing activity in preclinical models with the ability to robustly activate the immune system to drive durable, and sustained outcomes. Upcoming Expected Value-Driving Milestones Novel ADC's With Immuno-Oncology Payloads Anticipate presenting preclinical data showing that a proof-of-concept ADC with PH1 payload exhibits robust immuno-oncology activity, at a scientific conference in second half of 2025. Complete additional preclinical studies for novel PH1 payload exploring activity in prostate cancer cell lines. Explore preclinical activity for AKTX-101 in different solid tumor indications including lung, as single agent and in combination with other approved agents. Continue to focus on operational excellence and efficient capital allocation to advance novel payload ADC platform. Ongoing efforts to seek strategic partners for research collaborations on PH1 immuno-oncology payload across customized tumor targets. Continued discussions with partners on advancing AKTX-101 ADC (Trop2/PH1 payload) through additional IND-enabling activities. Non-Core Asset Out Licensing Continue efforts to out-license non-core assets across inflammation, ophthalmology, and rare diseases as a source of non-dilutive capital to invest into ADC platform. Summary of Financial Results for First Quarter 2025 The net loss from operations for the three months ended March 31, 2025 was approximately $3.7 million compared to $5.6 million for the same period in 2024. The Company reported research and development expenses of $0.8 million for the three months ended March 31, 2025 compared to approximately $2.3 million for the same period in 2024. The decrease was primarily due to our decision to suspend our HSCT-TMA clinical stage program with nomacopan in May 2024. General and administrative expenses were approximately $2.7 million for the three months ended March 31, 2025 compared to approximately $3.7 million for the same period in 2024. The decrease was primarily due to (i) decreases in legal and professional fees (primarily related to the Merger) and (ii) a decrease in directors' and officers' insurance. As of March 31, 2025, the Company had cash of approximately $2.6 million. The net proceeds from the Company's March 2025 offering, after deducting placement agent fees and other offering expenses, were approximately $6.0 million, of which $4.0 million was received in April 2025. About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads, the first being PH1. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates to any cancer tumor target of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells to deliver its novel PH1 immuno-oncology payload directly into the tumor cells. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome inhibitor designed to disrupt RNA splicing within cancer tumor cells. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its immuno-oncology payload PH1 to continue advancing its lead asset, AKTX-101, as well as developing ADCs against other undisclosed targets with its lead immuno-oncology payload, PH1. For more information about the Company, please visit and connect on X and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'future,' 'opportunity' 'will likely result,' 'target,' variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients; the Company's targets, plans, objectives or goals for future operations, including those related to its product candidates. These statements are based on the Company's current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company's programs or product candidates; risks related to any loss of the Company's patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company's product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company's product candidates; risks related to competition for the Company's product candidates; and the Company's ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 AKTX@ THERAPEUTICS, PLCCondensed Consolidated Balance Sheets(Amounts in thousands, except share and per share data)(unaudited) March 31, December 31, 2025 2024 ASSETS Current assets: Cash $ 2,582 $ 2,599 Restricted cash 60 60 Prepaid expenses 627 92 Other current assets 80 201 Total current assets 3,349 2,952 Goodwill 8,430 8,430 Other intangible assets 39,180 39,180 Total assets $ 50,959 $ 50,562 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 13,067 $ 12,407 Accrued expenses 3,494 3,137 Convertible notes 700 700 Convertible notes, related party 250 250 Notes payable 228 659 Notes payable, related party 668 1,651 Warrant liabilities 1,066 1,012 Liability related to deposits received for share subscriptions 950 — Other current liabilities 484 94 Total current liabilities 20,907 19,910 Other non-current liabilities 266 383 Deferred tax liability 8,040 8,040 Total liabilities 29,213 28,333 Commitments and contingencies (Note 13) Shareholders' equity: Share capital of $0.0001 par value Authorized: 245,035,791,523 ordinary shares at March 31, 2025 and December 31, 2024, respectively; issued and outstanding: 57,752,981,523 and 53,186,919,523 ordinary shares at March 31, 2025 and December 31, 2024, respectively 5,776 5,319 Additional paid-in capital 215,506 212,706 Capital redemption reserve 52,194 52,194 Accumulated other comprehensive loss (773 ) (738 ) Accumulated deficit (250,957 ) (247,252 ) Total shareholders' equity 21,746 22,229 Total liabilities and shareholders' equity $ 50,959 $ 50,562 AKARI THERAPEUTICS, PLCCondensed Consolidated Statements of Operations and Comprehensive Loss(amounts in thousands, except share and per share data)(unaudited) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development $ 813 $ 2,279 General and administrative 2,712 3,710 Total operating expenses 3,525 5,989 Loss from operations (3,525 ) (5,989 ) Other income (expense): Interest income — 2 Interest expense (55 ) — Gain on debt extinguishment 54 — Change in fair value of warrant liabilities (54 ) 649 Foreign currency exchange loss, net (125 ) (226 ) Other expense, net — (2 ) Total other (expense) income, net (180 ) 423 Net loss $ (3,705 ) $ (5,566 ) Net loss per share –– basic and diluted $ (0.00 ) $ (0.00 ) Weighted-average number of ordinary shares used in computing net loss per share –– basic and diluted 54,588,283,841 13,453,147,979 Comprehensive loss: Net loss $ (3,705 ) $ (5,566 ) Other comprehensive (loss) income, net of tax: Foreign currency translation adjustment (35 ) 279 Total other comprehensive (loss) income, net of tax (35 ) 279 Total comprehensive loss $ (3,740 ) $ (5,287 )Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
25-04-2025
- Business
- Zawya
Nigeria: GTCO shareholders approve $0.00497/ Share dividend payout
Shareholders of Guaranty Trust Holding Company (GTCO) Plc have approved the payment of a total dividend of N8.03 per share for the financial year ending December 31, 2024. This decision was made at the company's fourth annual general meeting, which was held virtually on Thursday. The company had previously paid an interim dividend of N1 per share and will now pay an additional N7.03 per share, bringing the total dividend for the 2024 financial year to N8.03 per share. Speaking to shareholders, the chairman of GTCO, Mr. Hezekiah Sola Oyinlola, emphasized the group's ability to remain agile and forward-thinking, which has allowed the company to achieve record-breaking performances. Oyinlola stated in his address at the AGM, 'In 2024, we became the first Nigerian bank to surpass the N1 trillion profit mark, an achievement that underscores the resilience of our business model, the dedication of our people, and the trust our customers place in us.' According to him, the company's success in a changing macroeconomic landscape is built on three pillars: operational excellence, disciplined risk management, and a relentless focus on customer-centric innovation. He noted that the banking business continues to demonstrate strong fundamentals, supported by a robust capital base and effective cost management. 'Our strategic diversification into payments, asset management, and pension fund administration has provided complementary revenue streams, reinforcing our leadership in the financial services sector,' he added. Also speaking on the group's 2024 performance, the Group Chief Executive Officer of GTCO, Mr. Segun Agbaje, noted, 'In 2024, we reached a historic milestone, delivering over N1 trillion in profit before tax, becoming the first Nigerian financial institution to achieve this feat.' He emphasized that its banking subsidiary, Guaranty Trust Bank, remains central to its operations, driving growth in Nigeria, West Africa, East Africa, and the United Kingdom. 'In 2024, we navigated a rapidly evolving regulatory and macroeconomic environment with a focus on strengthening our financial position and delivering best-in-class banking services,' he explained. Agbaje also noted that the Central Bank of Nigeria's recapitalization policy presented an opportunity to reinforce market leadership, allowing the group to complete the first phase of its equity capital raising plan through a Public Offer. 'This Public Offer attracted strong participation from both domestic retail and institutional investors, raising N209.41 billion and expanding our shareholder base from 332,000 to over 460,000,' he added. 'With this momentum, we are prepared to launch the second phase of our capital raising plan in 2025, targeting significant foreign institutional investments to further solidify our reputation as a globally recognized and competitive financial services brand,' he continued. Looking ahead, Agbaje stated, 'Our focus will be on deepening digitalization, enhancing customer experiences, and expanding our ecosystem of financial and non-financial solutions. We will continue to invest in cutting-edge technology, strengthen our cybersecurity framework, and build strategic partnerships that unlock new growth opportunities. Most importantly, we will remain true to our purpose: driving economic progress, fostering financial inclusion, and creating sustainable value for all stakeholders.' Shareholders commended the board for the financial performance achieved during the reviewed period, despite the challenging operating environment. Chief Timothy Adesiyan, speaking on behalf of shareholders, praised the management of GTCO for their impressive financial performance in 2024 and the dividend payout. Also, Mrs. Bisi Bakara, national coordinator of the Pragmatic Shareholders Association of Nigeria, commended the board, management, and staff for their stellar performance and success in the face of adversity. She expressed approval for the proposed final dividend declaration of N7.03 per share, which totals N8.03 in dividend payments. For the year ended December 31, 2024, GTCO reported a remarkable 81.1% surge in gross earnings, reaching N2.15 trillion, up from N1.19 trillion in 2023. Before the end of the AGM, Oyinlola also announced that, as part of the company's succession plan, Mr. Suleiman Barau has been appointed as the new Group Chairman, pending regulatory approval. He highlighted Barau's extensive experience and respect in the industry, noting that 'he is a former Deputy Governor of the Central Bank of Nigeria, with a proven track record of leadership and strategic insight.' 'He has been a pioneering director of GTCO since its restructuring. I am confident that under his guidance, GTCO will continue to thrive, innovate, and deliver superior value to all its customers and stakeholders,' he stated. Copyright © 2022 Nigerian Tribune Provided by SyndiGate Media Inc. (
Yahoo
10-02-2025
- Business
- Yahoo
Aspo Plc will publish its Financial Statements Release for year 2024 on February 17, 2025
Aspo PlcPress ReleaseFebruary 10, 2025, at 3.30 pmAspo Plc will publish its Financial Statements Release for year 2024 on February 17, 2025Aspo Plc will publish its financial statements release for year 2024 on Monday February 17, 2025 at approximately 8.00 a.m. Finnish time. A press, analyst and investor conference will be held at FLIK's Eliel studio in Sanomatalo, Töölönlahdenkatu 2, 00100 Helsinki on February 17, 2025 at 12.00 p.m. The event is also open to private investors, and participants are requested to register beforehand by emailing viestinta@ The financial statements release will be presented by CEO Rolf Jansson and CFO Erkka Repo. The presentation material will be available at before the conference. The event will be held in English, and it can also be followed by a live webcast at Questions can be asked after the event by telephone by registering through the following link: After registering, participants will be given a telephone number and identifier to participate in the telephone conference. The recording of the event will be available on the company's website later on the same day. Aspo PlcRolf JanssonCEO Further information:Rolf Jansson, CEO, Aspo Plc, tel. +358 400 600 264, Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these aiming to be forerunners in sustainability. Aspo supports its businesses profitability and growth with the right capabilities. Aspo Group has businesses in 17 different countries, and it employs approximately 800 professionals. Attachment 10.2.2025 Invitation Q4Sign in to access your portfolio
